Esophagectomy for Esophageal Cancer in a Patient with Protein C Deficiency: A Case Report

Ujiie, Naoto; Taniyama, Yusuke; Okamoto, Hiroshi; Sato, Chiaki; Tsuiki, Kai; Fukutomi, Toshiaki; Kamei, Takashi

doi:10.5761/atcs.cr.20-00129

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Good management of three patients with treatment using dried concentrated activated protein C and two patients using ZPC treatment was previously reported. 5,6,[9][10][11] In particular, Ceprotin and Protexel have been studied and are available in Europe and the United States. ZPC administration is not approved in Japan; further, dried concentrated activated protein C has not been used for perioperative management and such an agent is difficult to monitor.…”

Section: Discussionmentioning

confidence: 99%

Successful perioperative management using prothrombin complex concentrates in patients with severe congenital protein C deficiency

Inoue

Arakawa

Noguchi

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Perioperative management of severe congenital protein C deficiency remains unestablished. This deficiency is often treated with anticoagulants, such as warfarin. Although anticoagulants need to be perioperatively discontinued, there are few methods for the management of such patients. We adopted a method for administering prothrombin complex concentrates (PCC), which includes intermittent administration of inactive protein C (PPSB-HT), and examined its outcome as a perioperative management approach for severe congenital protein C deficiency. Three patients underwent our perioperative management six times. We monitored activity levels of protein C, factor IX, and so forth. These patients could be perioperatively managed with PCC treatment.

show abstract